Novartis reportedly in talks to buy MorphoSys; Astellas cuts PhII program; Silence’s $120M private placement

Plus, news about Adverum, BridgeBio Pharma, Vaxcyte, Corbus and Immunocore:

Novartis reportedly in deal talks with MorphoSys: The Swiss Big Pharma is in advanced talks to buy the German drugmaker, Reuters reported Monday, citing unnamed sources. The news outlet also reported that Incyte had made an offer. MorphoSys’ market cap is currently about $2.2 billion, and the biotech’s shares $MOR rose about 45% on the news. — Kyle LaHucik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Can ctDNA Guide Radiation Use in Oligometastatic NSCLC?

SAN DIEGO — A liquid biopsy may predict which patients with oligometastatic non-small cell lung cancer (NSCLC) are likely to benefit from consolidative targeted high-dose

October 6, 2023

T1D Stem Cell Success Story; Lilly’s Discount Tirzepatide Vials; Stelo Now Available

A type 1 diabetes patient talked about her successful treatment with an investigational stem cell therapy currently in trials, noting that she hasn’t needed insulin

August 28, 2024

Opinion | Remote Patient Monitoring Is a Great Idea. But What’s the Best Way to Use It?

Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director

October 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.